TMEM166 negatively regulates unfolded protein response to affect hepatocellular carcinoma cell growth and sorafenib resistance
8.5
来源：
Nature
关键字：
mRNA
发布时间：
2025-11-05 23:42
摘要：
TMEM166 is identified as a negative regulator of the unfolded protein response (UPR) in hepatocellular carcinoma (HCC). Its deletion enhances cell proliferation and resistance to sorafenib, a common treatment for HCC. The study reveals that TMEM166 interacts with ACSL3, maintaining lipid storage and influencing mitochondrial ATP production, which in turn activates UPR pathways. These findings suggest TMEM166's potential as a target for gene therapy strategies in HCC treatment.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分
business_impact
0.8分+0.8分
scientific_rigor
1.5分+1.5分
timeliness_innovation
1.5分+1.5分
investment_perspective
2.5分+2.5分
market_value_relevance
1.0分+1.0分
team_institution_background
0.5分+0.5分
technical_barrier_competition
1.0分+1.0分
关键证据
TMEM166 deletion promotes HCC cell proliferation and sorafenib resistance.
Study elucidates TMEM166's role in regulating UPR in HCC.
TMEM166 expression was negatively correlated with UPR activity in HCC.
真实性检查
否
AI评分总结
TMEM166 is identified as a negative regulator of the unfolded protein response (UPR) in hepatocellular carcinoma (HCC). Its deletion enhances cell proliferation and resistance to sorafenib, a common treatment for HCC. The study reveals that TMEM166 interacts with ACSL3, maintaining lipid storage and influencing mitochondrial ATP production, which in turn activates UPR pathways. These findings suggest TMEM166's potential as a target for gene therapy strategies in HCC treatment.